Amgen Says FDA Completes Review Of SNDA Seeking Full Approval For LUMAKRAS

RTTNews | 328 ngày trước
Amgen Says FDA Completes Review Of SNDA Seeking Full Approval For LUMAKRAS

(RTTNews) - Amgen, Inc. (AMGN) announced Tuesday that the U.S. Food and Drug Administration (FDA) has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS (sotorasib).

The review, which resulted in a Complete Response Letter, was based on the CodeBreaK 200 trial results for the treatment of adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).

The FDA also issued a new postmarketing requirement (PMR) for an additional confirmatory study to support full approval that will be completed no later than February 2028.

In addition, the FDA concluded that the dose comparison PMR issued at the time of LUMAKRAS accelerated approval, to compare the safety and efficacy of LUMAKRAS 960 mg daily dose versus a lower daily dose, has been fulfilled.

The company said LUMAKRAS at 960 mg once-daily will remain the dose for patients with KRAS G12C-mutated NSCLC under accelerated approval.

read more
Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris

Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris

The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab), developed by British drug major AstraZeneca's Rare Disease unit Alexion Pharmaceuticals, to treat certain rare diseases. Soliris is a medicine used to treat adults and children with paroxysmal nocturnal haemoglobinuria or PNH...
RTTNews | 173 ngày trước
Amgen Announces Positive Top-line Results From Phase 3 DAHLIA Study Of ABP 959

Amgen Announces Positive Top-line Results From Phase 3 DAHLIA Study Of ABP 959

Amgen, Inc. (AMGN) announced Tuesday positive top-line results from the DAHLIA study, a randomized, double-blind, active-controlled, two-period crossover Phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS (eculizumab), compared with SOLIRIS in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
RTTNews | 818 ngày trước
RBA Vigilant To Upside Risks To Inflation, Minutes Show

RBA Vigilant To Upside Risks To Inflation, Minutes Show

The Reserve Bank of Australia remained vigilant to upside risks to inflation and the board affirmed that the policy would need to be sufficiently restrictive until inflation moves sustainably towards the target, the minutes of the policy board meeting held on November 4 and 5 showed Tuesday.
RTTNews | 5h 47phút trước
Antipodean Currencies Rise As Asian Markets Trade Mostly Higher

Antipodean Currencies Rise As Asian Markets Trade Mostly Higher

Antipodean currencies such as the Australian and the New Zealand dollars strengthened against their major currencies in the Asian session on Tuesday, as traders picked up some stocks at a bargain after the recent weakness in the markets amid concerns about the outlook for interest rates. Strong gains in mining and energy stocks also boosted the markets amid climbing commodity prices.
RTTNews | 6h 14phút trước
Super Micro Stock Surges After Hiring New Auditor; Plans To Avoid Delisting

Super Micro Stock Surges After Hiring New Auditor; Plans To Avoid Delisting

Shares of Super Micro Computer Inc. surged around 40 percent in the extended trading on The Nasdaq Stock Market after the troubled server maker announced that it has hired a new auditor and filed a compliance plan with the stock exchange, with a view to avoiding its delisting. The plan was submitted to support its request for an extension of time to regain compliance with the Nasdaq...
RTTNews | 6h 28phút trước